18156, Improving Sickle Cell Disease OUtcomes: Treatment decision-making, curative therapies and overcoming barriers to care

Program ID #18156

Caring for patients with SCD is complex due to many factors, including the unpredictable course of the disease. Treatment decisions need to balance the morbidity and mortality that increase into adulthood with the potential risks and benefits of each treatment option. Additionally, barriers in access to care can affect quality of life for these patients throughout their disease course.

This enduring activity brings together critical perspectives to address these issues. Attendees will examine in-depth data on the latest treatment outcomes, upcoming clinical trials and new insights into shared decision-making between providers and patients.

Speakers include pediatric and adult hematologists, a clinical psychologist, and a young adult who chose hematopoietic cell transplantation (HCT) to treat SCD, and provides insight on how she and her family made this decision.

The session delves into what is known and not known about patient factors that weigh into the selection of therapeutic options, the potential for gene therapy and how information gained from clinical trials can influence treatment decisions.

Target Audience

Pediatric and adult hematologists, and health care professionals caring for patients with sickle cell disease (SCD).

Learning Objectives

  • Apply evidence-based guidelines for therapeutic decisions in SCD to improve patient outcomes.
  • Cite clinical trial results and the appropriate candidates for current SCD trials, including those utilizing HCT. 
  • Apply best communication practices in providing informed consent to patients and family to foster shared treatment decision-making. 
  • Identify strategies to overcome social and economic barriers for patients with SCD.
Additional information

CME Coordinator Contact Information

Name: 
Nicole Heino
Phone Number: 
+1 (763) 406-4811
Course summary
Available credit: 
  • 2.75 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 2.75 Hours of Participation
    Hours of Participation credit.
Course opens: 
04/09/2018
Course expires: 
04/09/2019
Cost:
$0.00
Planning Committee:
Linda Burns, MD
Mark Walters, MD
Lakshmanan Krishnamurti, MD
Greg Kato, MD
Elizabeth Murphy, EdD, RN
 
Presenters:

Introduction
Linda J. Burns, M.D.

National Marrow Donor Program® (NMDP)/Be The Match®, Minneapolis, Minn.

State of the field: SCD treatment strategies and standards of care
Gregory J. Kato, M.D.

University of Pittsburgh, Pittsburgh, Pa.

Future of the field: Curative therapies, including HCT for SCD, clinical trials and gene therapy
Mark C. Walters, M.D.

UCSF Benioff Children’s Hospital Oakland, Oakland, Calif.

Shared decision-making: Involving patients and families in treatment planning
Lakshmanan Krishnamurti, M.D.

Children’s Healthcare of Atlanta, Atlanta, Ga.

Ines Lukombo
Transplant recipient for SCD, Pittsburgh, Pa.

Partners in progress: Overcoming the social and economic barriers to SCD care
Marsha Treadwell, Ph.D.

UCSF Benioff Children’s Hospital Oakland, Oakland, Calif.

 

All persons in control of content have NO relevant financial relationships to disclose except:

NameCompanyRole
Gregory Kato, MDBayer, Global Blood Therapeutics, BiovertivResearch PI, Consultant
Marsha Treadwell, PhDPfizer Pharmaceuticals, Global Blood TherapeuticsConsultant
Mark Walters, MDAllCells Inc., Viacord Processing Lab, Bluebird Bio, Inc.Employment, Investigator

All persons in control of content have NO relevant financial relationships to disclose with the exception of the following and in accordance with the ACCME® standards for Commercial Support Number 6, these relationships were reviewed via the MCW conflict of interest resolution process and resolved.

ACCME Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and National Marrow Donor Program. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement: The Medical College of Wisconsin designates this Enduring Material for a maximum of 2.75 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals: The Medical College of Wisconsin designates this activity for up to 2.75 hours of participation for continuing education for allied health professionals.

Available Credit

  • 2.75 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 2.75 Hours of Participation
    Hours of Participation credit.

Accreditation Period

Course opens: 
04/09/2018
Course expires: 
04/09/2019

Price

Cost:
$0.00
Please login or register to take this course.